Do you have metastatic colorectal cancer? Does your cancer lack certain mutations? If so, you might be eligible to take part in a trial to look at the effects of an investigational anticancer drug given with normal therapy.

Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have thyroid cancer? If so, you may be eligible to participate in a research study to see which targeted therapy will work better to prolong the time until your tumor grows or spreads, after initial treatment.

This clinical trial is studying two different investigational treatments for patients with a blood disorder called myelodysplastic syndromes (MDS) who have a specific genetic mutation (IDH1) and have not been treated with certain drugs before. The study will compare the effects of two study drugs, Ivosidenib (IVO) and Azacitidine (AZA), given separately, to see how well they help patients. Researchers will track how many patients experience improvements, how long the treatment effects last, and overall survival.

Do you have incurable, metastatic, or recurrent head and neck squamous cell carcinoma? If so, you may be able to participate in a study to evaluate the addition of the anti-cancer drug, Cetuximab, to standard of care treatment.

Have you been diagnosed with early-stage breast cancer or ductal carcinoma in situ (DCIS) and have undergone breast conserving surgery (lumpectomy). If so this may be the research for you!! You may be able to take part in a research study to evaluate the effects of the tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with the WBI, as opposed to after the WBI.

Have you been diagnosed with a blood cancer that can be treated by transplant? If so, you might be eligible to take part in a study that will compare combinations of drugs to see which combination is better at preventing graft-versus-host disease.

The purpose of this study is to see if adding LY3537982 to standard cancer treatments works better than just using the standard treatments alone for people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated.

The purpose of this study is to test how safe and effective Volrustomig is when combined with other cancer treatments for people with specific types of tumors, specifically in the lung(s). The goal is to see if this combination can help treat the tumors better while being safe for patients.

Are you newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and looking for treatment options? Our study is evaluating new therapies specifically designed for patients with these conditions. If you have not previously tried an anti-cancer therapy for AML/MDS, this study might be for you!